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Abstract
Background—Tuberculosis (TB) remains a major cause of global morbidity and mortality, 
especially in the context of HIV co-infection, since immunity is not completely restored following 
antiretroviral therapy (ART). The identification of immune correlates of risk for TB disease could 
help in the design of host-directed therapies and clinical management. This study aimed to identify 
innate immune correlates of TB recurrence in HIV+ ART-treated individuals with a history of 
previous successful TB treatment.
Methods—Twelve participants with a recurrent episode of TB (cases) were matched for age, sex, 
time on ART, pre-ART CD4 count with 12 participants who did not develop recurrent TB in 60 
months of follow-up (controls). Cryopreserved peripheral blood mononuclear cells from time 
points prior to TB recurrence were stimulated with ligands for Toll like receptors (TLR) including 
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TLR-2, TLR-4, and TLR-7/8. Multi-color flow cytometry and intracellular cytokine staining was 
used to detect IL-1β, TNF-α, IL-12 and IP10 responses from monocytes and myeloid dendritic 
cells (mDCs).
Results—Elevated production of IL-1β from monocytes following TLR-2, TLR-4 and TLR-7/8 
stimulation was associated with reduced odds of TB recurrence. In contrast, production of IL-1β 
from both monocytes and mDCs following Bacillus Calmette-Guérin (BCG) stimulation was 
associated with increased odds of TB recurrence (risk of recurrence increased by 30% in 
monocytes and 42% in mDCs respectively).
Conclusion—Production of IL-1β by innate immune cells following TLR and BCG stimulations 
correlated with differential TB recurrence outcomes in ART-treated patients and highlights 
differences in host response to TB.
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INTRODUCTION
Tuberculosis (TB) is a global health problem causing nearly 10 million new infections every 
year. In particular, TB is the most common cause of death in HIV-infected individuals in 
Africa [1]. While TB infects approximately one third of the global population, the vast 
majority of these individuals readily contain TB infection, with only 5 to 10% developing 
active TB during their lifetime. A substantially higher risk of active TB does however exists 
in immunosuppressed individuals especially those with HIV co-infection [2].
South Africa has the highest burden of HIV and TB co-infection globally. Studies show that 
TB recurrence rates greatly depend on TB incidence and HIV prevalence [3–5]. A study 
conducted in South Africa reported that recurrent TB after successful treatment was up to 
four times that of new TB disease indicating a high risk of TB recurrence in people who 
experienced a TB episode [5]. Thus, factors that predispose individuals to TB acquisition 
may continue to play a role for susceptibility to TB recurrence as well.
Millenia of co-evolution with the host has equipped TB with many ways to elude natural 
immune defences and transit into a stage of relative dormancy [6–9]. Satisfactory control of 
TB would be best achieved using effective preventative TB vaccines. Progress in new TB 
vaccine development has been hampered by incomplete understanding of correlates of 
natural protection against TB that successful vaccines should emulate.
The continuum of host-pathogen interaction following infection with Mycobacterium 
tuberculosis (Mtb) to Mtb disease traverses innate immune, adaptive immune, quiescent and 
active replicating phases of infection. This continuum may extend beyond successful Mtb 
treatment when the cycle of TB re-infection may occur. In approximately 5% of treated 
patients live Mtb infection persists, which may subsequently cause a relapse of TB disease, 
whereas in others re-infection with Mtb may cause subsequent TB disease [10]. Several 
biomarkers have been described that reflects the biology of TB infection and or disease, 
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however to date no biomarker that accurately predicts latent, active TB or recurrent TB 
exists.
While the innate immune response is the first to encounter Mtb upon exposure, this arm of 
the immune system has not been well studied in the setting of TB in humans. Key immune 
cells that are the first contact include macrophages and dendritic cells, and these cells 
express Toll like receptors (TLRs) that recognize specific signatures on pathogens, initiating 
signaling pathways that trigger production of innate immune effector molecules, cytokines 
and chemokines. This response not only dictates the activity of the innate immune system, 
but is also critical in initiating the adaptive responses to Mtb likely leading to successful 
long-term containment [11]. Previous studies have implicated TLR-2 and TLR-4 in the 
direct recognition of Mtb [12, 13]. Data from a case-population study found a significant 
association between polymorphisms in a negative regulator gene of TLR/IL-1R signaling 
with increased TB susceptibility [14]. Additionally, an additive risk of TB susceptibility was 
observed with coinheritance of these polymorphisms and previously identified TLR risk 
alleles.
While antiretroviral therapy (ART) restores CD4 T cell numbers, effects of HIV infection on 
TB immunity are only partially reversed [15]. For example, reservoirs of HIV harbored in 
tissue macrophages make it difficult for eradication by ART and may lead to HIV-related 
neurological conditions [16, 17], and the impact of this reservoir on TB immunity in ART-
treated subjects is unknown [18]. Defects in myeloid dendritic cell and monocyte function 
may result in impaired cytokine production, which could render individuals more susceptible 
to TB.
The interleukin 1 (IL-1) and type 1 interferon (type 1 IFN) signaling pathways are well 
studied in mouse models but poorly understood in humans, and have been shown to play 
opposing roles in Mtb host resistance. Type-1 IFNs contribute to pathogenesis through 
impairment of host resistance to Mtb [19, 20] while IL-1β is required for host control of 
infection [21]. Thus the balance between the IL-1β and type 1-IFN responses is pivotal for 
host survival during Mtb infection. In line with this work, recent reports in mouse models 
revealed a mechanism behind the role of IL-1 in TB containment is mediated by the 
induction of prostaglandin E2 by IL-1 which limits production of type-1 IFNs [22]. The 
study by Mayer-Barber and others provided proof of concept that therapies directed against 
the host innate inflammatory response are possible and can alter TB outcome. Given the fact 
that immunological features of TB differs in mice and humans (e.g. characteristic tissue 
destruction preceding pulmonary cavitation is found in humans and not mice), validating 
these findings among HIV infected patients most vulnerable to TB disease is critical.
We evaluated whether differences in innate immunological factors mediated protection or 
risk of TB recurrence through investigation of antigen presenting cell (APC) responses 
following stimulation with TLR ligands in Mtb/HIV co-infected participants on ART with a 
previously-defined history of successfully treated pulmonary TB.
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Study Design and Cohort
We conducted a nested case control study among 24 virally suppressed HIV-infected 
patients from a larger prospective cohort of 520 subjects conducted between 2009 and 2014 
investigating the incidence of TB recurrence following successful TB treatment among 
stable patients on ART, the TB Recurrence upon Successful Treatment for Tuberculosis and 
HIV (TRuTH) study. All participants previously enrolled in a CAPRISA trial investigating 
timing of ART initiation during treatment for pulmonary TB [23] and with proven successful 
treatment for the previous TB episodes were eligible for enrolment into the TRuTH study. 
The TRuTH study screened participants quarterly over 60 months for TB recurrence, defined 
as first microbiologic confirmation of Mycobacterium tuberculosis by TB smear or TB 
culture. A total of 12 cases and 12 controls were selected from the overall cohort. Matching 
criteria for cases and controls included age (within a 5 year window), gender, study arm 
assignment in the previous trial, previous history of TB and baseline pre-ART CD4 count 
(within a 100 cells/μl window). Written informed consent was obtained from all study 
participants prior to enrolment and the University of KwaZulu-Natal Biomedical Research 
Ethics Committee approved the study (ref: BF 051/09; Clin trials.gov number NCT 
01539005).
Peripheral blood mononuclear cell (PBMC) samples were collected prospectively and stored 
at 3–6 month intervals. Among the 12 cases, two time-points before TB recurrence were 
studied; and compared to time-points from the matched control subjects. There were 42 
sample visits for the 12 controls, while for the 12 cases the number of sample visits in TB 
recurrent participants included pre-TB (n=16), untreated TB recurrence (n=11), TB 
treatment (n=13), and post-TB treatment (n=4).
In vitro stimulation of PBMCs with Toll-like receptor ligands
Cryopreserved PBMCs from cases and controls were thawed, re-suspended at 1 × 106 
cells/ml in R10 media [RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum 
(FCS), 100U/ml penicillin, 1.7nM sodium glutamate and 5.5ml HEPES buffer] and rested 
for 2 hours at 37°C, 5% CO2. One million cells were stimulated with pre-titrated amounts of 
the following antigens: 1μg/ml of heat killed Listeria monocytogenes (TLR-2 HKLM), 
1μg/ml Lipoarabinomannans from Mycobacterium smegmatis (TLR-2, LAM-MS), 0.1μg/ml 
of Lipopolysaccharide (TLR-4, LPS-EK), 1μg/ml thiazoloquinolone derivative (TLR-7/8, 
CL075); 75ng/ml of Trehalose-6,6-dibehenate (C-Type Lectin Receptor TDB), and 3μg/ml 
of Bacillus Calmette-Guérin (BCG). All ligands were from Invivogen aside from BCG 
(Statens Serum Institute). Samples with viability above 50% were used in experimental 
assays. The viability was not statistically different in cases and controls (median viability at 
baseline was 80% in cases and 64% in controls, P=0.17; and the median was 74% and 73% 
in cases and controls respectively for all time-points assessed (P=0.43). A negative control 
tube with PBMCs in media alone was included in all assays and for all analyses, cytokine 
production in stimulated samples was subtracted from the negative control with media alone. 
Brefeldin A (5μg/ml, Sigma) was added to all tubes immediately after adding the TLR 
ligands and stimulation of PBMCs was carried out for 18 hours at 37°C and 5% CO2. Due to 
Thobakgale et al. Page 4













sample limitations, stimulation with TB specific antigens LAM and TDB was performed in 
half of the participants.
Flow Cytometry
Following stimulation, PBMCs were washed with phosphate buffer saline (PBS) and stained 
for intracellular amine groups to differentiate live and dead cells using the aqua viability dye 
(Invitrogen) for 20 minutes at 4°C. Cells were then stained for 20 minutes at room 
temperature (RT) using monoclonal antibodies specific for the following surface markers: 
HLA-DR Pacific Blue (clone L243, Biolegend), CD14-APC CY7 (clone Mphip9), CD19-
Alexa Flour 700 (clone HIB19), CD56-Alexa Flour 700 (clone B159), CD3-Alexa Flour 700 
(clone UCHT1) and CD11c-PE Cy5 (clone B-ly6) (all from BD Biosciences). Cells were 
then washed, fixed with Fix/Perm Medium A (Caltag), and incubated for 20 minutes at RT. 
Cells were washed again, permeabilized (Fix/Perm B, Caltag) and stained for intracellular 
expression of: TNFα-PE Cy7 (clone MAb11), IL-12 (clone C11.5) APC, IL1β-FITC (clone 
AS10), IP10-PE (clone 6D4/D6/G2) (all from BD Biosciences) for 30 minutes at RT. Cells 
were finally washed and re-suspended in PBS before acquisition on an LRSII flow 
cytometer. At least 500,000 events were acquired per sample, and analyzed using the Flowjo 
software (version 9.4.11, TreeStar).
Statistical analyses
In order to assess the predictive value of cytokine expression on TB recurrence, a 
generalized estimating equations (GEE) model was fitted to case-control status, using a 
binomial distribution, accounting for possible repeated measures and controlling for 
matched variables. Cytokine concentrations measured at pre-TB time points were compared 
to all other time points from those individuals who never experienced a TB recurrence. 
Longitudinal assessment of IL-1β changes in APCs in participants with TB recurrence was 
done using Wilcoxon matched-pairs signed ranked test. Differences between groups and 
cytokine expression were considered statistically significant at the p<0.05 level. Statistical 
analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary) and graphs were 
plotted using Graphpad Prism (version 5).
RESULTS
Clinical characteristics of participant groups
The incidence rate of TB recurrence in the overall cohort was 4.07 % (95%CI. 3.24–5.06). 
The median CD4 count for the studied participants was not statistically different at 289 
cells/mm3 (IQR 105–470) for the cases and a median of 423 cells/mm3 (IQR 335–536) for 
the controls (p=0.2). The mean age was 34 years for the cases and 35 years for the controls 
and the cohort was predominantly female (67%) irrespective of the arm. The majority of the 
subjects were clinically stable, had their viral loads suppressed and had received ART for a 
median of 31 months (Table 1).
APC frequencies between cases and controls
We first assessed the frequencies of monocytes and myeloid dendritic cells (mDCs) in cases 
and controls. Monocytes were defined as HLA-DR+CD11c+CD14+ and mDCs as HLA-
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DR+CD14−CD11c+ following gating on live cells and exclusion of T cells, B cells and NK 
cells (CD3−CD19−CD56−) respectively (see gating strategy in Figure 1A). The median 
baseline frequency of monocytes was 2.5% (IQR 2.1–7.6) in cases and 1.88% (IQR 0.4–4.1) 
of HLA-DR positive live dump negative PBMCs in controls. We also evaluated the 
frequencies of monocytes of following stimulation and neither of the comparisons were 
statistically significant suggesting that the frequency of the monocytes were not predictors of 
TB outcome in this study (p=0.14 without stimulation, or BCG (p=0.2), LPS (p=0.4), 
HKLM (p=0.15), CL075 (p=0.47) stimulated (data not shown).
In contrast, the median frequency of mDCs in cases was significantly higher than in controls 
at baseline and following antigen stimulation, suggesting that this could be an indicator to 
predict TB recurrence. At baseline, mDCs were detected at 61.1% (IQR 50.3–68.6) and 
33.8% (IQR 20.7–57.3) of HLA-DR positive live dump negative PBMCs in controls (p=0.04 
for unstimulated, p=0.02 for BCG, p=0.02 for LPS, p=0.008 for HKLM and p=0.01 for 
CL075 stimulation, data not shown).
Decreased IL-1β and TNF-α expression in monocytes is associated with the risk of TB 
recurrence
We next assessed whether APC function, particularly early cytokine production signatures in 
both monocytes and mDCs of cases and controls would predict TB recurrence. We initially 
analyzed the predictive time-point (closest to TB recurrence) in cases compared to the 
matched time-point in the controls and found lower cytokine production in cases than in 
controls, however these differences were not statistically significant (data not shown). Next, 
a generalized estimating equations (GEE) model using binomial distribution was fitted to 
case-control status and corrected for repeated measures and matched variables. Only cases 
sampled at two time-points prior to TB recurrence and all control samples were analyzed. 
We found that increased IL-1β expression was significantly associated with protection from 
TB recurrence when stimulated with several antigens including LPS, HKLM, CL075 and 
that this response was mostly mediated by monocytes (Table 2, Figure 1B). For every 1% 
increase in IL-1β (in response to LPS stimulation) in monocytes, the odds of TB recurrence 
decreased by 6% (OR 0.94; 95%CI 0.89 – 1.00, p=0.04, Table 2). Similar data were 
observed for HKLM (OR 0.96; 95%CI 0.92 – 1.00, p=0.05) and CL075 (OR 0.95; 95%CI 
0.91 – 0.99, p=0.02). The expression of TNF-α, another pro-inflammatory innate mediator, 
was also decreased in monocytes following LPS stimulation in individuals who experienced 
TB recurrence (p=0.03, Table 2).
Interestingly, no similar observations were noted with regards to IL-1β production in mDCs 
following stimulation with multiple TLR stimulations with the exception of TDB 
(Supplementary Table 1), suggesting that this IL-1β defect in the cases is mediated by the 
monocytes. We instead observed that BCG stimulation was associated with 42% and 30% 
increased risk of TB recurrence per 1% increase in IL-1β expression in both mDCs and 
monocytes (OR 1.42; 95% CI 1.04 – 1.95; p=0.02; OR 1.30; 95% CI 1.09 – 1.55; p=0.003; 
in mDCs and monocytes respectively, Supplementary Table 1 and Table 2). In addition we 
also noted a similar pattern of increased odds of TB recurrence with IL-12 production in 
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response to HKLM stimulation only in mDCs, but not in response to other antigens or in 
monocytes. We did not observe any association of IP10 with TB recurrence.
Longitudinal changes in IL-1β expression amongst subjects with recurrent TB
We next investigated longitudinal changes in IL-1β levels beyond the predictive time-points 
in the TB recurrent group. Our findings showed a significant increase in IL-1β production on 
monocytes following LPS stimulation and only non-significant increase was noted for other 
stimulations during TB, however, these levels decreased following TB treatment suggesting 
that antigen load mediated the observed increase in the studied individuals. Differences were 
noted pre TB and during TB recurrence following stimulation with LPS (p=0.02) and a trend 
towards decreased IL-1β production was observed following CL075 stimulation during TB 
and post TB treatment (p=0.06). In addition, a trend towards higher IL-1β production was 
noted for CL075 stimulation following onset of TB recurrence and this decreased post TB 
treatment (p=0.07) in mDCs Fig 1C,D).
Taken together, our data show that the observed elevated production of IL-1β from 
monocytes following several antigen stimulations with TLR-2, TLR-4, TLR 7/8 may be 
associated with odds ratios of protection from TB recurrence and may therefore suggest that 
the status of the innate immune system, particularly impaired APC responses to TLR 
stimulation, may predict susceptibility to TB disease.
DISCUSSION
Factors that mediate protective immunity against Mtb are not fully understood and involve 
both innate and adaptive mechanisms. There is a need to identify biomarkers that accurately 
predict the risk of TB recurrence following successful treatment of TB, and define 
underlying immune mechanisms that may serve as vaccine or therapeutic targets. This study 
aimed to address this gap by investigating innate immune factors prospectively linked to TB 
outcomes. In particular, we investigated whether the functional status of antigen presenting 
cells confers protection or risk from TB recurrence amongst stable HIV-infected patients 
accessing ART with previous history of successful TB therapy.
Our findings show that of all cytokines tested following TLR stimulation; the overall 
expression of IL-1β, and to a lesser extent TNF-α, from monocytes was the best predictor of 
TB recurrence. We show that the cytokine production defect as demonstrated by lower IL-1β 
frequencies in the cases than in the controls was consistent across multiple TLR stimulations 
and may indicate a functional defect in monocytes following stimulation with TLR ligands. 
In addition, we demonstrated that APC responses to BCG stimulation were associated with 
increased risk of TB recurrence and may mark an important difference in innate host 
response to TB in cases compared to controls.
Phagocytes such as macrophages and dendritic cells are the first line of defense against TB, 
engulfing the bacilli and (if successful) limiting the severity of infection. They also alert the 
host to the presence of infection through pattern recognition of Mtb, thus coordinating the 
innate and subsequent adaptive host immune responses. The importance of IL-1β in 
mediating host response against TB has been previously reported [24]; and recent reports 
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show that IL-1β directly augments TNF-signaling, up-regulates TNF secretion and TNFR1 
cell surface expression leading to caspase-3 activation, apoptosis and direct killing of Mtb in 
macrophages [25]. Data from animal models and human clinical studies describe a network 
of pathways involving immune regulatory molecules that increase the risk of developing TB 
among which interleukins and interferons feature prominently [20, 21, 24, 26, 27]. Our 
findings on the IL-1β differences at the onset of TB are consistent with a report from a 
recent study conducted in mice infected with TB. The study demonstrated the importance of 
IL-1 in reducing disease severity through the induction of prostaglandin E2 levels (PGE2) 
that limit the production of type-I interferons, which are associated with increased TB 
disease severity [22]. The authors provided proof of concept for host-directed TB therapy 
and a potential for alternative options for TB infected individuals in the absence of a 
vaccine. We here make similar observations on the possible role of IL-1β in mediating TB 
containment, however the mechanism behind this defect or augmentation with some antigen 
stimulations requires further investigation in our cohort as well as in untreated HIV infected 
and HIV uninfected cohorts.
There are several other factors that could affect the innate immune system’s decreased 
capacity to respond, precipitating TB recurrence. Firstly, systemic inflammation that is not 
fully suppressed despite successful ART, may be an indication of low-level HIV-1 viremia 
and microbial translocation, which could be sources of continuous in vivo TLR stimulation 
of APCs. Secondly, Mtb can escape host recognition by inducing type 1 IFN that inhibits 
IL-1β release by macrophages and dendritic cells through suppression of IL-1β at 
transcriptional mRNA level [28, 29]. Expansion of patrolling monocytes with unusual 
phenotypes (CD16 expression and low levels of CD14) has been reported to be induced by 
HIV infection even in the presence of ART resulting in continuous TLR stimulation by the 
virus [30]. Host genetic factors may play a role in influencing the nature of the generated 
immune response [31, 32] accounting for the differences in outcome between the two study 
groups. Lastly, a defect in innate immunity as suggested by our findings or induced by any 
of the listed possible mechanisms, could result in failure to induce CD4+ T cell mediated 
immune responses well known to be fundamental to the control of Mtb. The above listed are 
some of the possible mechanisms that warrant follow-up investigation using this cohort. It 
was surprising to note that mDCs did not demonstrate a clear predictive outcome of TB risk 
with several antigens as noted for monocytes. Studies show that TB could induce 
impairment of dendritic cell maturation and increase IL-10 production known to suppress T 
cell response resulting in an imbalance of IFN- γ, enhanced IL-6 and IL-10 production and 
other causes implicated in low antigen-specific response and function associated with TB 
infection [33–35]. It is possible that the response of mDCs and monocytes to BCG as a risk 
factor for TB could be a pre-clinical response. Extremes in the ratio of peripheral blood to 
monocyte lymphocytes were found to be associated with increased risk of TB in HIV 
infected adults in South Africa and suggested to be a tool to stratify risk of TB [36]. In a 
separate study in infants who received BCG vaccination at birth and had higher monocyte to 
T cell ratios, transcriptional profiles were associated with an activated macrophage 
phenotype likely involved in pathogenesis of risk of TB disease suggesting that a phenotype 
of activated monocytes may be detrimental to the host [37]. It is thus important to classify 
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the monocyte subsets behind this IL-1β response in further studies as well as measure 
associated soluble markers of inflammation.
The ability of monocyte/macrophages and myeloid dendritic cells (mDCs) to modulate 
immune responses relevant to TB immunity has been demonstrated [38, 39]. The long TLR 
stimulations employed in our study, the low frequency and identification of monocytes from 
frozen samples are some of the study limitations that warrant further interrogation in future 
studies. Nevertheless, our findings from a well described prospective cohort of HIV/TB co-
infected individuals following multiple TLR stimulations of innate cells suggest that innate 
immune signaling may be an important predictor of TB pathogenesis. In particular, 
production of IL-1β by innate immune cells following TLR and BCG stimulations correlated 
with differential TB recurrence outcomes in ART-treated patients and highlights differences 
in host response to TB. While this is a pilot study with a very small participant sample size 
and needs to be validated in a larger cohort, with accompanying exploration of the innate 
mechanisms, it nonetheless supports recent findings and provides evidence in humans that 
IL-1β levels may have an impact on reactivation of TB. The study may therefore have public 
health implications calling for a need to identify individuals at risk for TB reactivation for 
host-directed therapies to reverse or reduce TB severity in TB endemic areas in the future.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Representative gating strategy and measurement of all cytokines (IL-1β, IP10, TNF-α and 
IL-12) in monocytes (HLA-DR+CD11c+CD14+) and myeloid dendritic cells (mDCs; HLA-
DR+CD14−CD11c+) following stimulation with TLR-7/8 ligand (CL075). (A) Gating was 
initially on lymphocytes followed by exclusion of cell doublets; dead cells, T cells, B cells 
and NK cell exclusion using the live/dead exclusion dye and CD3, CD19 and CD56 markers 
respectively followed by gating on HLA-DR positive cells. PBMCs were either unstimulated 
or stimulated with TLR-7/8 ligand (CL075) and all cytokine responses are shown for 
monocytes (HLA-DR+CD11c+CD14+), for first 2 rows and (mDCs; HLA-
DR+CD14−CD11c+) for the last 2 rows in a control subject without TB recurrence (no TB) 
shown on the left panel or in an individual who experienced TB recurrence (case), shown of 
the right panel. Monocytes and mDC gates were each derived from the lineage negative 
followed by gating on HLA-DR positive cells. Initial representative gating strategy (top row) 
refers to an unstimulated sample. (B) Representative predictive (0–6mo & 6mo time points) 
cytokine (IL-1β) response profiles in monocytes (top panel) and mDCs (bottom panel) of 
individuals with TB recurrence (cases) during successful treatment of TB prior to TB 
recurrence (TB) versus controls (NTB) over time. Only cases sampled prior to TB 
recurrence (0–6mo & 6mo time-points) were analyzed as well as all control samples. Box 
and whiskers represent individual IL-1β responses in cases (red) and controls (blue, for 
monocytes or green for mDCs); the p-value refers to differences in IL-1β production 
between cases and controls at the predictive time-points (also referred to in Table 2 
(monocytes) and Suppl Table 1 (mDCs) (C–D). Longitudinal assessment of IL-1β changes 
in monocytes (C) and mDCs (D) at pre-TB (n=16), during (n=11) and post TB (n=17) time-
points in the TB recurrence group. Assessment of IL-1β changes in monocytes and mDCs of 
participants with TB recurrence was done using Wilcoxon matched-pairs signed ranked test. 
Lines represent median with inter-quartile range. Fewer time points were analyzed for 
monocytes compared to mDCs due to cell availability from cryopreserved PBMC.
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Table 1
Baseline characteristics for nested case-control study participants, overall and stratified by TB recurrence 
outcome.
Characteristic All (n=24) TB recurrence (n=12) No TB recurrence (n=12)
Age in years at pre-ART; Mean (SD) 34.7 (6.11) 34.2 (5.73) 35.2 (6.67)
 Min to max 24 – 47 24 – 43 24 – 47
Female; n (%) 16 (66.7%) 8 (66.7%) 8 (66.7%)
Integrated arm; n (%) 16 (66.7%) 8 (66.7%) 8 (66.7%)
Previous history of TB; n (%) 14 (58.3%) 7 (58.3%) 7 (58.3%)
Pre-ART CD4 count, cells/μl; Mean (SD) 113 (72.06) 114 (73.85) 113 (73.50)
 Min to max 11 – 237 11 – 237 11 – 230
Pre-ART Log viral load, copies/ml; Mean (SD) 5.10 (0.83) 5.14 (0.70) 5.08 (1.00)
 Min to max 2.60 – 6.18 3.62 – 6.15 2.60 – 6.18
Current time on ARVs in years*; Median (IQR) 2.5 (1.9 – 3.6) 3.1 (1.4 – 1.3) 2.5 (0.7 – 1.6)
Current CD4 count, cells/μl; Mean (SD) 453 (435.35) 466 (604.73) 439 (119.55)
Min to max 14 – 2188 14 – 2188 271 – 671
Current CD4 count, cells/μl; Median (IQR) 354 (271 – 519) 289 (105 – 470) 423 (335 – 536)
Min to max 14 – 2188 14 – 2188 271 – 671
Current viral load suppressed**; n/N (%) 19/23 (82.6%) 8/12 (66.7%) 11/11 (100%)
Weight, kg; Mean (SD) 58.2 (8.75) 59.1 (9.16) 57.3 (8.62)
Body mass index; Mean (SD) 21.6 (3.42) 21.9 (3.62) 21.4 (3.36)
Cavitory disease at occurrence; n (%)
 No 16 (66.7%) 7 (58.3%) 9 (75.0%)
 One lung 5 (20.8%) 2 (16.7%) 3 (25.0%)
 Both lungs 3 (12.5%) 3 (25.0%) 0 (0.0%)
Infiltrates at occurrence; n (%)
 No 0 (0.0%) 0 (0.0%) 0 (0.0%)
 One lung 7 (29.2%) 1 (8.3%) 6 (50.0%)
 Both lungs 17 (70.8%) 11 (91.7%) 6 (50.0%)
Adenopathy at occurrence; n (%)
 No 23 (95.8%) 12 (100%) 11 (91.7%)
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Characteristic All (n=24) TB recurrence (n=12) No TB recurrence (n=12)
 One lung 1 (4.2%) 0 (0.0%) 1 (8.3%)
 Both lungs 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pleural infusion at occurrence; n (%)
 No 21 (87.5%) 12 (100%) 9 (75.0%)
 One lung 3 (12.5%) 0 (0.0%) 3 (25.0%)
 Both lungs 0 (0.0%) 0 (0.0%) 0 (0.0%)
*
One TB recurrence case was not on ARVs at the time of enrolment on TRUTH and the pre-TB time point was a month prior to initiating 
treatment.
**
One patient, who did not experience TB recurrence, did not have VL data available at the first time point measured. Current refers to the very 
first time-point CD4 and VL were measured and duration of time on ARVs in this substudy.
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